Instructions for Lavomax Neo (tilorone)
Release form Lavomax Neo:
film-coated tablets
Owner / Registrar Lavomax Neo (tilorone):
NIZHFARM, JSC
International Classification of Diseases (ICD-10)
Respiratory tuberculosis, bacteriologically and histologically confirmed
Chlamydial infections of the lower urinary tract
Chlamydial infections of the pelvic organs and others
Chlamydial pharyngitis A60
Anogenital herpes viral infection [herpes simplex]
Viral meningitis
Herpesviral [herpes simplex] infections
Chickenpox [varicella]
Shingles [herpes zoster]
Acute hepatitis
Acute hepatitis
Acute hepatitis
Chronic viral hepatitis b without delta agent B18.2
Chronic viral hepatitis C
Cytomegalovirus disease
Encephalitis, myelitis and encephalomyelitis
Acute upper respiratory tract infection, unspecified
Influenza caused by an identified influenza virus
Chlamydial pneumonia
Urethritis and urethral syndrome
Tiloron
Pharmacological group Lavomax Neo:
Antiviral and immunomodulatory drug. Interferon synthesis inductor
pharmachologic effect Lavomax Neo:
Antiviral Tiloron and immunomodulatory drug Tiloron. Lavomax stimulates the formation of α-, β-, γ-interferons in the body. In response to the introduction of Lavomax, interferon is produced mainly by intestinal epithelial cells, hepatocytes, T-lymphocytes and neutrophils.
After taking the drug Tiloron inside the maximum production of interferon is defined in a sequence of the liver-intestine-blood after 4-24 hours. Lavomax ® possesses immunomodulatory and antiviral effect. Stimulates bone marrow stem cells, increases antibody production depending on the dose, reduces the degree of immunosuppression, restores the T-helper / T-suppressor ratio.
Effective against various viral infections, incl. against influenza viruses, other acute respiratory viral infections, hepatitis and herpes viruses, cytomegalovirus and neurotropic viruses.
The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.
Pharmacokinetics Lavomax Neox:
Suction
After taking the drug Tiloron inside, tilorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%.
Distribution
Plasma protein binding is about 80%
Metabolism and excretion
Tilorone does not undergo biotransformation and does not accumulate in the body. It is excreted almost unchanged in the feces (about 70%) and urine (about 9%). T 1/2 is 48 hours.
Possible: short-term chills, allergic reactions, symptoms of dyspepsia.
Overdose Lavomax Neo:
The cases of drug overdose Lavomax unknown.
special instructions Lavomax:
Influence on the ability to drive vehicles and use mechanisms
The use of the drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Application during pregnancy and lactation Lavomax:
Lavomax is contraindicated in pregnancy and lactation (breastfeeding).
Antiviral immunostimulating agent
Indications Lavomax Neo:
As part of complex therapy in adults:
treatment of influenza and other acute respiratory viral infections, prevention of influenza in children and adults
treatment of herpes infection of various forms
Drug interactions Lavomax Neo:
No clinically significant interaction of Lavomax/Tiloron with antibiotics, standard therapy for viral and bacterial diseases, alcohol has been identified.
Compatible with antibiotics and standard therapy for viral and bacterial diseases.
How to take Lavomax Neox:
The drug Tiloron is taken orally, after meals.
In the treatment of influenza and other acute respiratory viral infections - in the first two days of the disease - 125 mg, then every other day, 125 mg. Heading dose - 750 mg (for a course of treatment - 6 tablets, 125 mg each).
For the prevention of influenza and other acute respiratory viral infections - 125 mg 1 time per week for 6 weeks. For the course of treatment - 6 tab. 125 mg each.
For the treatment of viral hepatitis A - the first day, 125 mg 2 times, then 125 mg every other day. Heading dose - 1.25 g (for a course of treatment - 10 tablets, 125 mg each).
For the treatment of acute hepatitis B - the first and second days, 125 mg, then 125 mg every other day. Heading dose - 2 g (for a course of treatment - 16 tablets, 125 mg each), with a prolonged course of hepatitis B - 125 mg 2 times / day on the first day, then 125 mg every other day. The course dose is 2.5 g (for a course of treatment - 20 tablets, 125 mg each).
In chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days, 250 mg each, then 125 mg every other day. Continuation phase (from 1.25 g to 2.5 g) - 125 mg per week.
The course dose of Lavomax/Tiloron is from 3.75 to 5 g (for a course of treatment - from 30 to 40 tablets, 125 mg each), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process. Tiloron
In acute hepatitis C - the first and second days, 125 mg, then 125 mg every other day. Heading dose - 2.5 g (for a course of treatment - 20 tablets, 125 mg each).
In chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days, 250 mg each, then 125 mg every other day. Continuation phase (2.5 g) - 125 mg per week. The course dose of Lavomax/Tiloron is 5 g (for a course of treatment - 40 tablets, 125 mg each). The duration of therapy is 6 months, depending on the results of biochemical, immunological, morphological markers of the process activity.
For the treatment of herpes, cytomegalovirus infection - the first two days, 125 mg, then every other day, 125 mg. Heading dose - 2.5 g (for a course of treatment - 20 tablets, 125 mg each).
With urogenital and respiratory chlamydia, non-gonococcal urethritis - the first two days, 125 mg each, then every other day, 125 mg. Heading dose - 1.25 g (for a course of treatment - 10 tablets, 125 mg each).
As part of the complex therapy of pulmonary tuberculosis - the first two days, 250 mg, then 125 mg every other day. Heading dose - 2.5 g (for a course of treatment - 20 tablets, 125 mg each).
As part of the complex therapy of neuroviral infections, the dose is set individually, the course of treatment is 4 weeks.
Storage conditions and shelf life Tiloron
The drug Tiloron should be stored out of the reach of children, in a dry, dark place at a temperature not exceeding 25 ° C. Shelf life is 2 years.
Dispensing from pharmacies:
The drug is approved for use as a means of OTC.
Tiloron
